Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603223 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
A Phase 2 study of Leukoplakia and Erythroleukoplakia, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT03603223 is a Phase 2 study of Leukoplakia and Erythroleukoplakia that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 26 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT03603223, a Phase 2 study of Leukoplakia and Erythroleukoplakia, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II pilot trial studies how well pembrolizumab works in treating leukoplakia. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
Study Locations (3)
California
- UC San Diego Moores Cancer Center - La Jolla
- USC / Norris Comprehensive Cancer Center - Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-05-03 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03603223
The ClinicalTrials.gov registry entry for NCT03603223 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Leukoplakia appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03603223 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03603223 about?
NCT03603223 is a clinical study titled "Pembrolizumab in Treating Participants With Leukoplakia". This phase II pilot trial studies how well pembrolizumab works in treating leukoplakia. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
What is the current status of trial NCT03603223?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2019-05-03. Estimated completion is 2027-08-01.
What conditions does trial NCT03603223 study?
This clinical trial studies the following conditions: Leukoplakia, Erythroleukoplakia, Verrucous Oral Leukoplakia.
What interventions are being tested in trial NCT03603223?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03603223?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03603223 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukoplakia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.